Objective: ADAMTS5 (aggrecanase-2) has been demonstrated to be crucial in the development of osteoarthritis (OA), by use of several mouse mutants carrying either truncated, catalytically inactive enzymes or aggrecanase-resistant mutant aggrecan. We have selected recombinant monoclonal antibodies directed against ADAMTS5, by using Intracellular Antibody Capture Technology (IACT). CRB0017 revealed very high affinity for the enzyme in Biacore analyses and very good specificity in a panel of binding assays. Therefore, we tested CRB0017 in a relevant spontaneous OA model, the STR/ort mouse. Design: STR/ort male mice were recruited at 5 months of age, and treated intra-articularly in each knee with CRB0017 1.2 mg, CRB0017 12 mg, or vehicle. After 6 weeks, the intra-articular administration of CRB0017 was repeated with the same doses. After 3 months from recruitment, the animals were sacrificed and the femorotibial joints processed for histology and scored in a blind fashion according to both Mankin's and the OARSI methods.
Introduction
The etiology of osteoarthritis (OA), the most widespread form of arthritis, is largely unknown. Breakdown of aggrecan, the most represented non-collagenous protein in articular cartilage, is an early event in the onset and progression of OA, and therefore since their discovery aggrecanases have been postulated to have a role in OA, which has been recently widely demonstrated in relevant animal models. Mouse mutants lacking functional ADAMTS5 (aggrecanase-2) are protected from articular cartilage loss in a relevant OA surgical paradigm 1 , as are mice carrying aggrecanaseresistant mutant aggrecan 2 . As a consequence, ADAMTS5 has since been regarded as an appealing possible therapeutic target for OA 3 .
In order to evaluate a possible therapeutic approach to OA via biologic interference with ADAMTS5, we have used the proprietary Intracellular Antibody Capture Technology (IACT) to select a panel of antibody domains from large recombinant scFv SPLINT libraries 4e6 . The antibodies were selected using different and specifically engineered domains of ADAMTS5 as antigens.
In particular, mAb CRB0017 7 demonstrated very high affinity for the spacer domain of the enzyme (as revealed by Biacore assays) both in the single chain and in the IgG4 format. Moreover, the antibody was shown to reduce the proteolytic activity of the enzyme in vitro with an IC 50 in the low nanomolar range. Therefore, this antibody was selected for further drug development. To verify the hypothesis that interfering with the biological activity of ADAMTS5 could improve the course of OA, we tested mAb CRB0017 in STR/ort mice, which develop a spontaneous, age-related OA and are considered a relevant model for human OA 8e11 .
Methods

mAb CRB0017 production and purification
Anti-ADAMTS5 CRB0017 scFv was reformatted to IgG4 antibody for expression in mammalian cells. CHO-S cells were stably transfected with plasmids encoding CRB0017 heavy and light chains. Clarified supernatant was loaded onto HiTrap protein A-sepharose column (GE Healthcare) previously equilibrated with PBS. The antibody was recovered by acidic elution (10 mM HCl pH 2.5) followed by immediate neutralization with 1 M TriseHCl pH 8.5. Pooled fractions were dialyzed against PBS.
Animal model
Male STR/ort mice (Harlan, Italy) were housed with ad libitum access to food and water, in a temperature-controlled room with a 12 h light/dark cycle. All the experimental procedures described were in compliance with international laws and policies (Directive 2010/63/EU revising Directive 86/609/EEC on the protection of animals used for scientific purposes; Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) . STR/ort mice were recruited at 5 months of age (n ¼ 20e22/ treatment group), randomly distributed by treatment in each cage, with four animals per cage, weighed and treated intra-articularly, each in both knees with single dosing of either CRB0017 1.2 mg, CRB0017 12 mg, or vehicle (in a final volume of 4 ml). The control group consisted only of vehicle treated mice as we never observed any significant differences between mice treated with an irrelevant IgG4 and vehicle treated mice in our previous experiments (data not shown). After 6 weeks the intra-articular administration of CRB0017 was repeated with the same doses. After 3 months from recruitment the animals were sacrificed and hind limbs explanted and fixed in formalin o/n. Knees were embedded in paraffin, 4-micron thick sections were produced and stained with toluidine blue and then scored in a blind fashion according to both Mankin's and the OARSI scores 12, 13 . Total score represents the OARSI score plus cell loss plus GAG loss scores. This takes into account all parameters that were reported separately in order to provide the best detail, allowing a further and more complete view on OA progression as a whole. Since OA develops independently in each joint of each single STR/ort mouse 8e11 , both knees were injected. Accordingly, the joints were scored independently for each animal. To support this approach, during the setup phase of the analysis model, we investigated the presence of a correlation between the right and left knee scores in control groups of mice treated either with vehicle or with an irrelevant human IgG4 in three different experiments (including the control group of the present study, in total 75 mice). This analysis showed that the correlation between the pathology scores evaluated in right and left knees is very low, if any, and never statistically significant, in spite of the large number of animals involved (data not shown). Statistical analysis was performed by KruskaleWallis ANOVA on ranks followed by Dunn's test comparing each treatment group vs vehicle.
Results
As we aimed for a therapeutic protocol, and not a preventive one, 5-month-old male STR/ort mice were enrolled for this experiment. At this age, 100% of male STR/ort mice display some degree of OA. Mice were monitored daily for the duration of the experiment, and showed general well being; no deaths or weight loss were observed, nor other relevant signs of toxicity. Three months after the first injection, vehicle treated mice displayed severe OA with clefting, fibrillation and erosion of articular cartilage, sclerosis and focally necrosis of subchondral bone, osteochondrophytes and pathological changes in ligaments and capsula [ Fig. 1(a) ].
All OA histopathological scores were dose-dependently reduced following treatment with CRB0017, with the higher dose reaching a profound, statistically significant decrease vs vehicle, for all parameters [ Fig.1(b) and 2 ]. This experiment was repeated twice with the same protocol, yielding the same results (data not shown).
Discussion
Since the discovery of its importance in OA onset and progression, ADAMTS5 has been pursued as a target for therapies aimed at disease modification, with strategies employing design of small molecules to inhibit its protease activity 3, 14 . Unfortunately this search has been rewarded with little success, likely because of the high homology of the catalytic domain across the diverse metalloprotease families, and the resulting difficulties at achieving specificity in order to avoid a burden of undesired effects. With the aim of developing a therapeutic approach to OA devoid of off-target side effects, we attempted to interfere with ADAMTS5's function by means of a biological agent. Therefore, we undertook extensive selective screening of recombinant scFv libraries to isolate specific antibodies directed against single domains of ADAMTS5. The best candidate for therapeutic development was mAb CRB0017, which demonstrated excellent affinity (K D in low nanomolar range), and high selectivity for its antigen 7 . A previous study has highlighted the possibility of targeting ADAMTS5's exosites in its ancillary domain as a possible therapeutic strategy to reduce its activity 15 . In order to obtain a proof of concept for this approach, we studied the effects of CRB0017 in our animal model of choice for OA, the STR/ort mouse. We selected intra-articular administration in view of its compliance in osteoarthritic patients for a treatment that is assumed to be once in several weeks, and arguably should reduce the risk of side effects in virtue of the low amount of compound used.
As a possible limitation of the STR/ort model it is to be acknowledged that in mice at 5 months of age (i.e., at the beginning of the follow-up) it is not possible to have a baseline observation nor to select a signal joint (i.e., the worst joint) that could be followed during the pathology progression, as usually done in human studies. Nevertheless, as above detailed, we demonstrated the absence of any statistically significant correlation between the pathology scores evaluated in right and left knees in control animals treated with vehicle or with an irrelevant human IgG4. On these bases, we believe that in these specific experimental conditions considering each joint as independent does not bias the validity of the results. Therefore, both knees were injected, and scored independently for each animal.
Another possible limitation of the study is that it is not possible to determine how much of the activity observed can be due to the local activity of CRB0017 injected or to a systemic activity of the mAb that possibly leaks from the synovial space, since no quantitative bioanalytical methods were applied to detect the circulating CRB0017. Although, due to the high local concentration of mAb, the former hypothesis seems more probable, this issue will be addressed in further studies in which the effect of a systemic administration will be compared to that of an intra-articular injection with the same dose level, in addition assessing the mAb circulating levels with a properly validated method.
In conclusion, mAb CRB0017 administered twice in 3 months indeed modified the course of OA in the STR/ort mouse, by delaying cartilage breakdown as assessed histologically. The procedure of blind scoring of the histological samples clearly showed a dose dependent effect of the antibody in reducing the severity of the osteoarthritic pathology in the STR/ort mice. Taken together, these data show that knee intra-articular administration of mAb CRB0017, an anti-ADAMTS5 monoclonal antibody targeting an ancillary domain, dose-dependently improved disease progression in a relevant animal model of OA. To the best of our knowledge, this is the first report on the efficacy of a recombinant mAb against ADAMTS5 in OA disease modification; we believe that the data here presented suggest a possible novel therapeutic approach for OA.
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